Sign In

Brandon Fenn

Partner at Cooley

Brandon W. Fenn is a partner at Cooley LLP, based in New York.2 He specializes in representing companies at all stages of their life cycle, with a focus on life sciences and technology sectors.2 Brandon's expertise includes:

  1. Advising on initial public offerings and other capital markets transactions
  2. Venture capital financings
  3. Mergers and acquisitions (M&A) transactions
  4. General corporate matters for both private and public companies
  5. Public company governance and reporting

Brandon became a partner at Cooley LLP on January 1, 2021, as part of a class of 16 new partners elected by the firm.1 He received his B.A. from Dartmouth College and earned his J.D. from New York University School of Law.3

In his role, Brandon has been involved in several significant transactions, including:

  • Advising Enavate Sciences on its investment in Aviceda Therapeutics' $207.5 million Series C financing (January 2025)2
  • Representing Nuvolo in its agreement to be acquired by Trane Technologies (October 2023)2
  • Advising Tourmaline Bio on its merger with Talaris Therapeutics (June 2023)2
  • Counseling VectivBio on its $1 billion acquisition by Ironwood (May 2023)2
  • Advising Oyster Point Pharma on its acquisition by Viatris (November 2022)2

Brandon's LinkedIn profile can be found at linkedin.com/in/brandon-fenn-b18bb45.

Related Questions

What are some notable deals Brandon Fenn has worked on?
How did Brandon Fenn transition from corporate law to life sciences and technology?
What is Brandon Fenn's educational background?
How does Brandon Fenn's practice differ from other corporate partners at Cooley LLP?
What are the key industries Brandon Fenn focuses on?
Brandon Fenn
Brandon Fenn, photo 1
Brandon Fenn, photo 2
Add to my network

Location

New York, New York, United States